Frontiers in Immunology (Mar 2024)

Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection

  • Emilie Goguet,
  • Emilie Goguet,
  • Cara H. Olsen,
  • William A. Meyer,
  • Sara Ansari,
  • John H. Powers,
  • Tonia L. Conner,
  • Si’Ana A. Coggins,
  • Si’Ana A. Coggins,
  • Wei Wang,
  • Richard Wang,
  • Luca Illinik,
  • Luca Illinik,
  • Margaret Sanchez Edwards,
  • Margaret Sanchez Edwards,
  • Belinda M. Jackson-Thompson,
  • Belinda M. Jackson-Thompson,
  • Monique Hollis-Perry,
  • Gregory Wang,
  • Gregory Wang,
  • Yolanda Alcorta,
  • Yolanda Alcorta,
  • Mimi A. Wong,
  • Mimi A. Wong,
  • David Saunders,
  • Roshila Mohammed,
  • Roshila Mohammed,
  • Bolatito Balogun,
  • Bolatito Balogun,
  • Priscilla Kobi,
  • Priscilla Kobi,
  • Lakeesha Kosh,
  • Lakeesha Kosh,
  • Kimberly Bishop-Lilly,
  • Regina Z. Cer,
  • Catherine E. Arnold,
  • Catherine E. Arnold,
  • Logan J. Voegtly,
  • Logan J. Voegtly,
  • Maren Fitzpatrick,
  • Maren Fitzpatrick,
  • Andrea E. Luquette,
  • Andrea E. Luquette,
  • Francisco Malagon,
  • Francisco Malagon,
  • Orlando Ortega,
  • Orlando Ortega,
  • Edward Parmelee,
  • Edward Parmelee,
  • Julian Davies,
  • Julian Davies,
  • Alyssa R. Lindrose,
  • Alyssa R. Lindrose,
  • Hannah Haines-Hull,
  • Hannah Haines-Hull,
  • Matthew S. Moser,
  • Matthew S. Moser,
  • Emily C. Samuels,
  • Emily C. Samuels,
  • Marana S. Rekedal,
  • Marana S. Rekedal,
  • Elizabeth K. Graydon,
  • Elizabeth K. Graydon,
  • Allison M. W. Malloy,
  • David R. Tribble,
  • Timothy H. Burgess,
  • Wesley Campbell,
  • Sara Robinson,
  • Christopher C. Broder,
  • Robert J. O’Connell,
  • Carol D. Weiss,
  • Simon Pollett,
  • Simon Pollett,
  • Eric D. Laing,
  • Edward Mitre

DOI
https://doi.org/10.3389/fimmu.2024.1287504
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionWe sought to determine pre-infection correlates of protection against SARS-CoV-2 post-vaccine inzfections (PVI) acquired during the first Omicron wave in the United States.MethodsSerum and saliva samples from 176 vaccinated adults were collected from October to December of 2021, immediately before the Omicron wave, and assessed for SARS-CoV-2 Spike-specific IgG and IgA binding antibodies (bAb). Sera were also assessed for bAb using commercial assays, and for neutralization activity against several SARS-CoV-2 variants. PVI duration and severity, as well as risk and precautionary behaviors, were assessed by questionnaires.ResultsSerum anti-Spike IgG levels assessed by research assay, neutralization titers against Omicron subvariants, and low home risk scores correlated with protection against PVIs after multivariable regression analysis. Commercial assays did not perform as well as research assay, likely due to their lower dynamic range.DiscussionIn the 32 participants that developed PVI, anti-Spike IgG bAbs correlated with lower disease severity and shorter duration of illness.

Keywords